Efficacy and Safety of Antiepileptic Drug Treatments in Epilepsy Management

Epilepsy is a chronic neurological disorder affecting over 50 million people worldwide and is managed primarily through antiepileptic drug (AED) therapy, which seeks to achieve optimal seizure control while minimising adverse effects. First-line monotherapy choices—such as lamotrigine for focal epilepsy or valproate for generalised tonic–clonic seizures—are guided by efficacy, tolerability and cost considerations. Nevertheless, up to one-third of patients experience refractory seizures, necessitating adjunctive strategies with newer agents including perampanel, lacosamide and eslicarbazepine. Advances in trial design, network meta-analysis and real-world observational studies have refined our understanding of comparative efficacy and safety profiles, highlighting the importance of individualised dosing, therapeutic drug monitoring and consideration of special populations such as children and the elderly. Common adverse events—dizziness, somnolence and behavioural changes—must be balanced against long-term effects on cognition and mood. Emerging biomarkers and precision-medicine approaches promise further optimisation of regimen selection. This summary integrates current evidence on AED efficacy and safety, emphasising global relevance and practical applications for clinicians and researchers.

Research from Nature Portfolio

A comprehensive network meta-analysis compared second- and third-generation AEDs as adjunctive therapy in refractory epilepsy by integrating direct and indirect evidence across multiple trials. Topiramate ranked highest for achieving a 50 percent responder rate, while levetiracetam offered a balanced profile of efficacy and tolerability regarding dizziness and somnolence. This framework, utilising surface under the cumulative ranking curves, informs selection of optimal agents in treatment-resistant cases.

Efficacy and Safety of Antiepileptic Drug Treatments in Epilepsy Management publication trend

The graph below shows the total number of articles in efficacy and safety of antiepileptic drug treatments in epilepsy management across all publications each year (not limited to Nature Index journals).

Technical terms

Monotherapy: Treatment with a single antiepileptic drug without concurrent additional AEDs.

Adjunctive therapy: Use of an additional AED alongside a primary treatment to enhance seizure control.

50% responder rate: Proportion of patients achieving at least a 50 percent reduction in seizure frequency from baseline.

Seizure freedom rate: Proportion of patients remaining free of seizures over a predefined observation period.

Network meta-analysis: Statistical method combining direct and indirect evidence from multiple trials to compare and rank treatments.

Retention rate: Percentage of patients remaining on a given medication after a specified follow-up, reflecting tolerability and perceived benefit.

References

1. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. The Lancet (2021).
2. Efficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis. Scientific Reports (2017).
3. PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice. Journal of Neurology (2021).
4. Efficacy and safety of perampanel monotherapy in patients with focal‐onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open‐label Study 342 (FREEDOM Study). Epilepsia Open (2020).